A
Price
$124.16
Change
+$2.86 (+2.36%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
42.66B
40 days until earnings call
ICLR
Price
$152.23
Change
+$1.70 (+1.13%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
27.35B
13 days until earnings call
Interact to see
Advertisement

A vs ICLR

Header iconA vs ICLR Comparison
Open Charts A vs ICLRBanner chart's image
Agilent Technologies
Price$124.16
Change+$2.86 (+2.36%)
Volume$18.72K
Capitalization42.66B
ICON
Price$152.23
Change+$1.70 (+1.13%)
Volume$34.9K
Capitalization27.35B
A vs ICLR Comparison Chart in %
Loading...
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICLR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
A vs. ICLR commentary
Jul 11, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is A is a Buy and ICLR is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 11, 2025
Stock price -- (A: $121.30 vs. ICLR: $150.53)
Brand notoriety: A and ICLR are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: A: 87% vs. ICLR: 66%
Market capitalization -- A: $42.66B vs. ICLR: $27.35B
A [@Medical Specialties] is valued at $42.66B. ICLR’s [@Medical Specialties] market capitalization is $27.35B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.58B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

A’s FA Score shows that 1 FA rating(s) are green whileICLR’s FA Score has 0 green FA rating(s).

  • A’s FA Score: 1 green, 4 red.
  • ICLR’s FA Score: 0 green, 5 red.
According to our system of comparison, A is a better buy in the long-term than ICLR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

A’s TA Score shows that 4 TA indicator(s) are bullish while ICLR’s TA Score has 5 bullish TA indicator(s).

  • A’s TA Score: 4 bullish, 4 bearish.
  • ICLR’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, ICLR is a better buy in the short-term than A.

Price Growth

A (@Medical Specialties) experienced а +0.53% price change this week, while ICLR (@Medical Specialties) price change was -0.19% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +1.93%. For the same industry, the average monthly price growth was +1.46%, and the average quarterly price growth was +0.94%.

Reported Earning Dates

A is expected to report earnings on Aug 19, 2025.

ICLR is expected to report earnings on Oct 22, 2025.

Industries' Descriptions

@Medical Specialties (+1.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
A($42.7B) has a higher market cap than ICLR($27.4B). ICLR has higher P/E ratio than A: ICLR (44.81) vs A (34.82). A YTD gains are higher at: -9.324 vs. ICLR (-28.220). A has higher annual earnings (EBITDA): 1.69B vs. ICLR (1.52B). A has less debt than ICLR: A (2.56B) vs ICLR (3.94B). ICLR has higher revenues than A: ICLR (8.12B) vs A (6.74B).
AICLRA / ICLR
Capitalization42.7B27.4B156%
EBITDA1.69B1.52B111%
Gain YTD-9.324-28.22033%
P/E Ratio34.8244.8178%
Revenue6.74B8.12B83%
Total CashN/A380M-
Total Debt2.56B3.94B65%
FUNDAMENTALS RATINGS
A vs ICLR: Fundamental Ratings
A
ICLR
OUTLOOK RATING
1..100
2123
VALUATION
overvalued / fair valued / undervalued
1..100
20
Undervalued
70
Overvalued
PROFIT vs RISK RATING
1..100
62100
SMR RATING
1..100
4776
PRICE GROWTH RATING
1..100
5463
P/E GROWTH RATING
1..100
5697
SEASONALITY SCORE
1..100
n/a95

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

A's Valuation (20) in the Biotechnology industry is somewhat better than the same rating for ICLR (70) in the Pharmaceuticals Other industry. This means that A’s stock grew somewhat faster than ICLR’s over the last 12 months.

A's Profit vs Risk Rating (62) in the Biotechnology industry is somewhat better than the same rating for ICLR (100) in the Pharmaceuticals Other industry. This means that A’s stock grew somewhat faster than ICLR’s over the last 12 months.

A's SMR Rating (47) in the Biotechnology industry is in the same range as ICLR (76) in the Pharmaceuticals Other industry. This means that A’s stock grew similarly to ICLR’s over the last 12 months.

A's Price Growth Rating (54) in the Biotechnology industry is in the same range as ICLR (63) in the Pharmaceuticals Other industry. This means that A’s stock grew similarly to ICLR’s over the last 12 months.

A's P/E Growth Rating (56) in the Biotechnology industry is somewhat better than the same rating for ICLR (97) in the Pharmaceuticals Other industry. This means that A’s stock grew somewhat faster than ICLR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AICLR
RSI
ODDS (%)
Bearish Trend 2 days ago
45%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
57%
Bearish Trend 2 days ago
66%
Momentum
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
67%
MACD
ODDS (%)
Bullish Trend 2 days ago
70%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
66%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 2 days ago
65%
Advances
ODDS (%)
Bullish Trend 2 days ago
61%
Bullish Trend 9 days ago
67%
Declines
ODDS (%)
Bearish Trend 11 days ago
60%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
71%
Aroon
ODDS (%)
Bullish Trend 2 days ago
60%
Bullish Trend 2 days ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ICLR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
BRKD24.010.34
+1.43%
Direxion Daily BRKB Bear 1X Shares
IBIJ25.700.10
+0.38%
iShares iBonds Oct 2033 Term Tips ETF
NMAI12.620.04
+0.32%
Nuveen Multi-Asset Income Fund
RAAX31.810.09
+0.30%
VanEck Real Assets ETF
IBDR24.16-0.01
-0.04%
iShares iBonds Dec 2026 Term Corp ETF

ICLR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ICLR has been closely correlated with IQV. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ICLR jumps, then IQV could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ICLR
1D Price
Change %
ICLR100%
-0.69%
IQV - ICLR
75%
Closely correlated
-1.49%
RGEN - ICLR
62%
Loosely correlated
+0.98%
TMO - ICLR
55%
Loosely correlated
-1.48%
A - ICLR
54%
Loosely correlated
+0.24%
BRKR - ICLR
54%
Loosely correlated
-0.57%
More